Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03109847 · ClinicalTrials.gov registry record · Phase 2
Metformin to Mitigate Sequelae of Radioactive Iodine Treatment for Thyroid Cancers
A Phase 2 study, sponsored by Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University.
- Terminated
- Registry status
- Phase 2
- Development phase
- 13
- Enrollment target
NCT03109847 is a Phase 2 study that was terminated before completion, run by Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University. The registered enrollment target is 13 participants.
The verdict
NCT03109847, a Phase 2 study, was terminated before completion, sponsored by Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 13 participants
- Enrollment target
Study Summary
This pilot clinical trial studies how will metformin hydrochloride works in mitigating the side effects of radioactive iodine treatment in patients with differentiated thyroid cancer. Metformin hydrochloride may reduce the metabolic activity of cancer cell and of surrounding supportive tissues.
Interventions
- OTHER Placebo
- DRUG Metformin Hydrochloride
- OTHER Radioactive Iodine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13 participants |
| Start Date | 2017-01-05 |
| Est. Completion | 2022-12-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03109847
The ClinicalTrials.gov registry entry for NCT03109847 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 13 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University, which has 138 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT03109847 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03109847 about?
NCT03109847 is a clinical study titled "Metformin to Mitigate Sequelae of Radioactive Iodine Treatment for Thyroid Cancers". This pilot clinical trial studies how will metformin hydrochloride works in mitigating the side effects of radioactive iodine treatment in patients with differentiated thyroid cancer. Metformin hydrochloride may reduce the metabolic activity of cancer cell and of surrounding supportive tissues.
What is the current status of trial NCT03109847?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 13 participants. The study started on 2017-01-05. Estimated completion is 2022-12-07.
What interventions are being tested in trial NCT03109847?
The interventions under investigation include: Placebo (OTHER), Metformin Hydrochloride (DRUG), Radioactive Iodine (OTHER).
Who is sponsoring clinical trial NCT03109847?
This trial is sponsored by Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University, which has 138 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.